|Dr. Leen Kawas||CEO, Pres & Director||706.47k||N/A||1986|
|Ms. Glenna K. Mileson||CFO & Corp. Sec.||417.64k||N/A||1959|
|Dr. Hans Moebius||Chief Medical Officer||425.06k||N/A||1957|
|Dr. Mark J. Litton M.B.A., Ph.D., MBA||Chief Operating Officer||N/A||N/A||1968|
|Mr. Robert Renninger||Director of Accounting & Reporting||N/A||N/A||N/A|
|Ms. Rachel P. Lenington||CTO & Head of Product Devel. Strategy||N/A||N/A||N/A|
|Mr. Mark F. Worthington||Gen. Counsel||N/A||N/A||N/A|
|Dr. Kevin Church Ph.D.||VP of Discovery||N/A||N/A||1985|
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 9.